R-CDOP Regimen in the Treatment of Newly Diagnosed Non-Hodgkin's Lymphoma With High Tumor Burden

Más betegség

• Hypersensitivity to any study drug or its ingredients;
• Patients with significant and uncontrolled cardiovascular disease or history;
• Persons with mental disorders/unable to obtain informed consent;
• Previous history of malignant tumor;
• HIV infection; HBV infection (HBV-DNA> 2000 IU/ml);HCV infection (HCV-RNA>200 IU/ml);

Laborértékek

• Abnormal liver function [total bilirubin > 1.5 times of the upper limit of normal value; Alanine aminotransferase/Aspartate aminotransferase (ALT / AST) > 2.5 times of upper limit of normal value for patients without liver metastasis ; ALT / AST > 5 times of upper limit of normal value for patients with liver metastasis ], abnormal renal function (serum creatinine > 1.5 times of upper limit of normal value) ;
• Absolute Neutrophil Count (ANC)<1.5×10\^9/L or Platelet (PLT)< 75 × 10\^9/L;

Életkor

• Pregnant or lactation and patients of childbearing age who do not want to take contraceptive measures;

Egyéb

• Lymphoma infiltrates the central nervous system;
• The investigator determined not suitable to participate in this study.

• Histologically immunohistochemistry and imaging confirmed diffuse large B-cell lymphoma or follicular lymphoma grade 3B;
• Has at least one evaluable or measurable lesion according to Lugano response criteria;
• Patients with at least one of the following high tumor burden Involvement of at least 3 nodal sites (each with a diameter greater than 3 cm); nodal or extranodal mass > 7cm in its greater diameter; Hepatomegaly and splenomegaly (infiltration confirmed by PET-CT; Spleen: female > 15cm, male > 16cm); Pleural/peritoneal effusion; Lactate dehydrogenase (LDH) three times the upper limit of normal; PET-CT TMTV >220cm3;
• Patients previously untreated;
• Patients aged over 18 and under 75 years;
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0~2;
• International Prognostic Index (IPI) score > 1, or with extranodal mass diameter ≥7cm;
• Life expectancy ≥ 6 months;
• Left Ventricular Ejection Fraction (LVEF) ≥ 50%;
• Patients must sign informed consent and be willing and able to comply with the requirements of visits, treatment, laboratory tests and other research requirements stipulated in the research schedule.